Driving precision oncology adoption now
May 18, 2020
May 18, 2020
The days of one-size-fits-all therapies are being replaced by individualized treatments and disease interventions. In cancer, standard therapies are ineffective in an average of three-quarters of patients, one of the highest therapy failure rates for all diseases.1 Precision oncology holds the promise of improved efficiency, better care and the reduction of ineffective treatments and costs. However, important work remains to prepare the oncological ecosystem to leverage the full potential. To test the status quo, identify barriers to adoption and help unlock precision oncology’s full value, we surveyed 130 oncologists from the US and Europe as part of the Accenture Study on Precision Oncology in Practice.
Oncologists say they need:
85%
of respondents rank outcomes/longitudinal data as the most critical data source to share.
20%
or less of oncologists today do not routinely participate in any molecular tumor boards or routinely use CDS tools.
66%
of oncologists believe that clinical practice is changing rapidly and will require them to master new skillsets.
It’s clear that precision oncology’s importance will grow significantly in the next few years, but to achieve the desired goals, a clear course must be plotted. Our research shows the oncology ecosystem requires four essential steps to capture the full potential of precision oncology:
Physicians need support through seamless exchange with peers and experts, and CDS tools using advanced analytics and RWE to interpret patient data.
We must expand the oncological data ecosystem across borders and drive a common approach to data collection, accreditation and standardization.
We need digital technology and genomics education to interpret molecular foundations of each individual cancer in technology-enabled solutions.
Precision oncology adds complexity to everyday clinical practice. We need to align to clinical workflow, integrate technology and collaborate.
1 Spear, B. B., Heath-Chiozzi, M. & Huff, J. Clinical application of pharmacogenetics. Trends Mol. Med. 7, 201–204 (2001)